Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Multi-Center, Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess the Antidepressant Effect and Onset of Effect of AZD6765 in Treatment-Resistant Major Depressive Disorder Patients

NCT00491686 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00491686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00491686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Multi-Center, Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess the Antidepressant Effect and Onset of Effect of AZD6765 in Treatment-Resistant Major Depressive Disorder Patients
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2007
Completion date
November 30, 2007
Enrollment
34 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

depression